Plus Therapeutics’ (PSTV) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note released on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock.

Separately, Ascendiant Capital Markets cut their price target on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

Plus Therapeutics Stock Performance

NASDAQ PSTV opened at $1.26 on Tuesday. Plus Therapeutics has a fifty-two week low of $1.12 and a fifty-two week high of $2.67. The stock has a market cap of $7.43 million, a P/E ratio of -0.50 and a beta of 0.69. The stock has a 50 day simple moving average of $1.36 and a two-hundred day simple moving average of $1.62.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC bought a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.